Table 2.

Clinical studies using MSC-based therapies for cancer treatment

Form of drug	Cancer applications	Interventions	Phase	NCT NO
Tissue-derived MSC	Hematopoietic and lymphoid cell neoplasm	Cord blood MSCs	I/II	NCT04565665
	Acute leukemia	IFNγ-primed bone marrow MSCs	I	NCT04328714
	Pancreatic cancer	Adipose MSCs	I	NCT04087889
	Mandible tumor	Adipose MSCs	I/II	NCT03678467
	Acute respiratory distress syndrome (ARD) in patients with malignancies	Bone marrow MSCs	I	NCT02804945
	Myelodysplastic syndromes	Cord blood MSCs	I/II	NCT03184935
	Rectal cancer	NeuroRegen Scaffold™ + Cord blood MSCs	I/II	NCT02648386
	Hematologic malignancies	MSCs	I	NCT02181478
	Prostate cancer	Bone marrow MSCs	I	NCT01983709
	Expanding umbilical cord blood derived blood stem cells for treating leukemia, lymphoma, and myeloma	Bone marrow MSCs	I/II	NCT01624701
	Solid organ cancers	MSCs	I	NCT01275612
	Hematological malignancies	Cord blood transplantation + MSCs	I/II	NCT01092026
	Leukemia, lymphoma, and myeloma	Hematopoietic stem cells + MSCs	II	NCT01045382
	Bone neoplasms	Pre-immunodepleted MSCs	II/III	NCT00851162
	Myelodysplastic syndromes	Cord blood MSCs	II	NCT01129739
Engineered MSC	Ovarian cancer	MSCs secreting INF-β	I	NCT02530047
	Adenocarcinoma of lung	MSCs secreting TRAIL + standard therapy	I	NCT03298763
	Diffuse intrinsic pontine glioma	Radio therapy + Bone marrow MSCs infected with oncolytic virus	I	NCT04758533
	Glioma	Bone marrow MSCs infected with oncolytic virus	I	NCT03896568
	Head and neck cancer	MSCs secreting IL-12	I	NCT02079324
	Ovarian, primary peritoneal or fallopian tube cancer	Adipose MSCs infected with oncolytic virus	I/II	NCT02068794
	Metastatic and refractory tumors	Bone marrow MSCs infected with oncolytic virus	I/II	NCT01844661
MSC-derived exosome	Metastatic pancreas cancer	MSCs-derived exosomes with KRAS G12D siRNA	I	NCT03608631